NO20043902L - Kontrollert syntese av ziprasidon og sammensetninger derav - Google Patents

Kontrollert syntese av ziprasidon og sammensetninger derav

Info

Publication number
NO20043902L
NO20043902L NO20043902A NO20043902A NO20043902L NO 20043902 L NO20043902 L NO 20043902L NO 20043902 A NO20043902 A NO 20043902A NO 20043902 A NO20043902 A NO 20043902A NO 20043902 L NO20043902 L NO 20043902L
Authority
NO
Norway
Prior art keywords
ziprasidone
compositions
controlled synthesis
synthesis
controlled
Prior art date
Application number
NO20043902A
Other languages
English (en)
Norwegian (no)
Inventor
Frank Robert Busch
Jr Harry Ralph Howard
Adam Worth Grobin
Kyle Robert Leeman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27761437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20043902(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20043902L publication Critical patent/NO20043902L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
NO20043902A 2002-02-20 2004-09-17 Kontrollert syntese av ziprasidon og sammensetninger derav NO20043902L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35880602P 2002-02-20 2002-02-20
US35903802P 2002-02-21 2002-02-21
US36045902P 2002-02-27 2002-02-27
PCT/IB2003/000642 WO2003070246A1 (en) 2002-02-20 2003-02-17 Controlled synthesis of ziprasidone and compositions thereof

Publications (1)

Publication Number Publication Date
NO20043902L true NO20043902L (no) 2004-09-17

Family

ID=27761437

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20043902A NO20043902L (no) 2002-02-20 2004-09-17 Kontrollert syntese av ziprasidon og sammensetninger derav
NO20100584A NO20100584L (no) 2002-02-20 2010-04-22 Fremgangsmate ved bruk av HPLC for a male mengden 5-(2-kloretyl)-1,3-dihydro-2H-indol-on i et preparat omfattende 6-klor-5-(2-kloretyl)-1,3 dihydro-2H-indol-2-on

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20100584A NO20100584L (no) 2002-02-20 2010-04-22 Fremgangsmate ved bruk av HPLC for a male mengden 5-(2-kloretyl)-1,3-dihydro-2H-indol-on i et preparat omfattende 6-klor-5-(2-kloretyl)-1,3 dihydro-2H-indol-2-on

Country Status (41)

Country Link
EP (1) EP1476162B1 (sr)
JP (1) JP4554938B2 (sr)
KR (1) KR100773622B1 (sr)
CN (2) CN1635892A (sr)
AP (1) AP2004003103A0 (sr)
AR (1) AR038563A1 (sr)
AT (1) ATE359787T1 (sr)
AU (2) AU2003206035A1 (sr)
BR (1) BR0307833A (sr)
CA (1) CA2475302C (sr)
CO (1) CO5611138A2 (sr)
CY (1) CY1106467T1 (sr)
DE (1) DE60313289T2 (sr)
DK (1) DK1476162T3 (sr)
EA (1) EA007866B1 (sr)
EC (1) ECSP045239A (sr)
ES (1) ES2283745T3 (sr)
GE (1) GEP20074030B (sr)
GT (1) GT200300040A (sr)
HR (1) HRP20040711A2 (sr)
IL (1) IL163277A (sr)
IS (1) IS7344A (sr)
MA (1) MA27177A1 (sr)
MX (1) MXPA04006993A (sr)
MY (1) MY139523A (sr)
NO (2) NO20043902L (sr)
NZ (1) NZ534443A (sr)
OA (1) OA12774A (sr)
PA (1) PA8567001A1 (sr)
PE (1) PE20030942A1 (sr)
PL (1) PL372238A1 (sr)
PT (1) PT1476162E (sr)
RS (1) RS60404A (sr)
SI (1) SI1476162T1 (sr)
SV (1) SV2004001485A (sr)
TN (1) TNSN04159A1 (sr)
TW (1) TW200307546A (sr)
UA (1) UA77057C2 (sr)
UY (1) UY27668A1 (sr)
WO (1) WO2003070246A1 (sr)
ZA (1) ZA200406276B (sr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101230034A (zh) 2000-03-06 2008-07-30 阿卡蒂亚药品公司 用于治疗5-羟色胺相关性疾病的氮杂环化合物
NZ571695A (en) 2001-12-28 2010-02-26 Acadia Pharm Inc Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
CA2490397A1 (en) 2002-06-24 2003-12-31 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
US7488729B2 (en) 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
US7601740B2 (en) 2003-01-16 2009-10-13 Acadia Pharmaceuticals, Inc. Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
WO2004083192A1 (en) 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd. Polymorphis of valsartan
TW200505879A (en) * 2003-04-21 2005-02-16 Teva Pharma Process for the preparation of valsartan
EP1546146A1 (en) 2003-06-03 2005-06-29 Teva Pharmaceutical Industries Limited POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
WO2005040160A2 (en) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
US20050197347A1 (en) * 2003-12-18 2005-09-08 Judith Aronhime Polymorphic form B2 of ziprasidone base
DE602005018171D1 (de) 2004-02-27 2010-01-21 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
BRPI0516063A (pt) 2004-09-27 2008-08-19 Acadia Pharm Inc sìntese de n-(4-fluorbenzil)-n-(1-metilpiperidin-4-il)-n'-(4-(2-metilp ropi-loxi)fenilmetil)carbamida e seu sal tartarato e formas cristalinas
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
ES2250000B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Procedimiento para la preparacion de ziprasidona.
US20090163513A1 (en) * 2005-01-27 2009-06-25 Hetero Drugs Limited Process for ziprasidone using novel intermediates
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
CN100491375C (zh) * 2006-07-01 2009-05-27 浙江美诺华药物化学有限公司 一种齐拉西酮的制备方法
EP2134330B1 (en) 2007-03-19 2013-05-08 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
CN102234272A (zh) * 2010-04-21 2011-11-09 上海医药工业研究院 盐酸齐拉西酮半水合物的制备方法
SI3325444T1 (sl) 2015-07-20 2021-11-30 Acadia Pharmaceuticals Inc. Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US11464768B2 (en) 2016-12-20 2022-10-11 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
CN108239085A (zh) * 2016-12-26 2018-07-03 四川科瑞德凯华制药有限公司 一种甲磺酸齐拉西酮的纯化及制备方法
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
CN112724066B (zh) * 2021-02-04 2022-10-21 海南鑫开源医药科技有限公司 一种盐酸齐拉西酮中间体中的二卤杂质及其制备方法
CN116046966A (zh) * 2023-01-17 2023-05-02 北京协和建昊医药技术开发有限责任公司 一种流动相配置装置及其配置方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5206366A (en) 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
PT874834E (pt) 1995-11-07 2001-04-30 Pfizer Processos e intermediarios para preparacao de 3-(1-piperazinil)-1,2-benzisotiazole
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
ATE236902T1 (de) * 1996-05-07 2003-04-15 Pfizer Mesylat des trihydrats des 5-(2-(4-(1,2- benzothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor 1,3-dihydro-2(1h)-indol-2-ons (=ziprasidon), seine herstellung und seine anwendung als dopamin d2 antagonist
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
TW200307546A (en) 2003-12-16
JP4554938B2 (ja) 2010-09-29
CO5611138A2 (es) 2006-02-28
IS7344A (is) 2004-07-05
AP2004003103A0 (en) 2004-09-30
ES2283745T3 (es) 2007-11-01
NO20100584L (no) 2004-09-17
PL372238A1 (en) 2005-07-11
ECSP045239A (es) 2004-09-28
CN101735212A (zh) 2010-06-16
AU2003206035A1 (en) 2003-09-09
UY27668A1 (es) 2003-10-31
CA2475302A1 (en) 2003-08-28
EP1476162A1 (en) 2004-11-17
TNSN04159A1 (fr) 2007-03-12
GEP20074030B (en) 2007-02-12
MXPA04006993A (es) 2004-11-10
MA27177A1 (fr) 2005-01-03
SI1476162T1 (sl) 2007-08-31
IL163277A (en) 2010-05-31
PE20030942A1 (es) 2003-11-08
WO2003070246A1 (en) 2003-08-28
EA200400815A1 (ru) 2004-12-30
UA77057C2 (en) 2006-10-16
RS60404A (sr) 2006-10-27
SV2004001485A (es) 2004-05-07
PA8567001A1 (es) 2003-12-10
AU2009202008A1 (en) 2009-06-11
ZA200406276B (en) 2005-09-20
KR20040086417A (ko) 2004-10-08
DE60313289D1 (de) 2007-05-31
NZ534443A (en) 2007-07-27
CN1635892A (zh) 2005-07-06
JP2005525347A (ja) 2005-08-25
KR100773622B1 (ko) 2007-11-05
GT200300040A (es) 2007-01-12
HRP20040711A2 (en) 2004-12-31
CY1106467T1 (el) 2012-01-25
PT1476162E (pt) 2007-06-25
DK1476162T3 (da) 2007-07-02
AR038563A1 (es) 2005-01-19
MY139523A (en) 2009-10-30
OA12774A (en) 2006-07-04
BR0307833A (pt) 2004-12-07
CA2475302C (en) 2009-05-12
DE60313289T2 (de) 2007-12-27
ATE359787T1 (de) 2007-05-15
EA007866B1 (ru) 2007-02-27
EP1476162B1 (en) 2007-04-18

Similar Documents

Publication Publication Date Title
NO20043902L (no) Kontrollert syntese av ziprasidon og sammensetninger derav
NO20053890D0 (no) Syntese av 4amino-2-butenolklorider og anvendelse derav for fremstilling av 3-cyanokinoliner
DK1713544T3 (da) Sammensætninger og fremgangsmåder til oral og personlig pleje
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
EP1496894A4 (en) ANGIOGENESIS INHIBITORS
GB0323805D0 (en) Synthesis of germanium sulphide and related compounds
DE60317799D1 (de) Antimikrobielle zusammensetzung und anwendungsverfahren
EP1765336A4 (en) ANGIOGENESIS INHIBITORS
NO20044916L (no) Preparater av sulfinylacetamid
IS7467A (is) Lansóprasólfjölgervingar og aðferðir við að framleiða þá
NO20042433L (no) Syntese og rensing av valasyklovir
NO20043937L (no) Anvendelse av vitamin D sammensetninger
DK2305689T3 (da) Syntese af naturligt forekommende ecteinascidiner og relateredeforbindelser
DE60325741D1 (de) Breitbandsynthese von schmalbandigen signalen
EP1585519A4 (en) HIGH CONCENTRATION OPIOID FORMULATIONS AND OPIOID DERIVATIVES
NO20054095D0 (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater
DE60335143D1 (de) Mundpflegezusammensetzungen und -verfahren
DE60322926D1 (de) Photopolymerisierbare zusammensetzung und verwendung davon
AU2003212457A1 (en) Derivatives of epothilone b and d and synthesis thereof
DK1456377T3 (da) Syn3-sammensætninger og fremgangsmåder
NO20056162L (no) Kombinasjoner av vasobeskyttende agenser og formuleringer inneholdende dem
NO20042126L (no) Syntese av 2-aralkoksyadenosiner og 2-alkoksyadenosiner
NO20054346D0 (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
AU2003291458A8 (en) Pharmaceutical compositions and methods of using taxane derivatives
DE50308682D1 (de) Bausatz aus pflastersteinen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application